Loading
The 2022 World Health Organization classification redefines myeloid cancers, including myelodysplastic neoplasms, acute myeloid leukaemia by genetic type, and the boundaries between them.
Summary of the fifth-edition WHO classification of myeloid and histiocytic neoplasms, renaming myelodysplastic syndromes as myelodysplastic neoplasms, removing the 20 percent blast threshold for AML with defining genetic abnormalities, and reorganising AML, myeloproliferative neoplasms and secondary myeloid neoplasms around genetics.
The names and definitions on a marrow report (for example MDS with biallelic TP53 inactivation, or AML myelodysplasia-related) come from this document or from the parallel International Consensus Classification.
Shares Leukemia, Chronic myeloid leukaemia, accelerated and blast phase.
Shares Rosai-Dorfman-Destombes disease, Erdheim-Chester disease.
Shares Indolent and smouldering systemic mastocytosis, Rosai-Dorfman-Destombes disease, Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia), Erdheim-Chester disease.
Shares Rosai-Dorfman-Destombes disease, Erdheim-Chester disease.
Shares Indolent and smouldering systemic mastocytosis, Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia).
Shares Secondary and therapy-related acute myeloid leukaemia, Higher-risk myelodysplastic syndromes.
Shares Indolent and smouldering systemic mastocytosis, Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia), Erdheim-Chester disease.
Shares Indolent and smouldering systemic mastocytosis, Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia).